Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

9.8K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
9.8K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

5.9K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
5.9K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

1.9K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.9K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

9.2K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Toxicity Under-Reporting in Early-Phase Plasma Cell Dyscrasia Clinical Trial Abstracts.

JCO oncology practice·2026
Same author

Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study.

Leukemia & lymphoma·2026
Same author

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.

British journal of haematology·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026

Related Experiment Video

Updated: Oct 9, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.9K

Limited-stage diffuse large B-cell lymphoma.

Eliza A Hawkes1,2,3,4, Allison Barraclough1,4,5, Laurie H Sehn6,7

  • 1Olivia Newton-John Cancer Research Institute at Austin Health, Melbourne, VIC, Australia.

Blood
|December 21, 2021
PubMed
Summary

Limited-stage diffuse large B-cell lymphoma (DLBCL) has excellent survival, but evolving treatments aim to reduce relapse and radiotherapy toxicity. Positron-emission tomography (PET) scans guide personalized strategies for better outcomes.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.3K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

221

Related Experiment Videos

Last Updated: Oct 9, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.9K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.3K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

221

Area of Science:

  • Hematology
  • Oncology
  • Medical Imaging

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype.
  • Limited-stage DLBCL (LS-DLBCL) accounts for 25-30% of cases with a generally favorable prognosis (70-80% 10-year survival).
  • Evolving insights into disease biology and advanced imaging like PET scans are reshaping treatment paradigms for LS-DLBCL.

Purpose of the Study:

  • To provide a comprehensive review of recent literature on LS-DLBCL treatment.
  • To discuss evolving treatment strategies and recommendations for clinical practice.
  • To address challenges in LS-DLBCL definition and management, including relapse risks and radiotherapy complications.

Main Methods:

  • Review of recent clinical studies and literature on LS-DLBCL.
  • Analysis of treatment strategies including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy.
  • Evaluation of positron-emission tomography (PET) scan utility in staging and response assessment.

Main Results:

  • No standard definition for LS-DLBCL exists, causing interpretation challenges.
  • R-CHOP remains a cornerstone, often combined with radiation therapy.
  • Strategies like abbreviated immunochemotherapy and PET-adapted radiotherapy are being explored to minimize toxicity and optimize outcomes.

Conclusions:

  • Rigorous staging and PET-based response assessment are crucial for informed decision-making in LS-DLBCL.
  • Minimizing treatment toxicities while maintaining efficacy is a key focus.
  • Integration of updated literature and strategies into clinical practice is recommended for LS-DLBCL patients.